Business
Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates
Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitorSix abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the
About this update from Eikon Therapeutics, Inc.
[{"type":"image","alt":"Eikon Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Eikon Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":194,"url":"https://media.zenfs.com/en/globenewswire.com/4244084826f1ce90c788c046545dcf21"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CHhUx_SPC_mefYX2YC_FDg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3Mg--/https://media.zenfs.com/en/globenewswire.com/4244084826f1ce90c788c046545dcf21","width":300,"height":194},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/CHhUx_SPC_mefYX2YC_FDg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3Mg--/https://media.zenfs.com/en/globenewswire.com/4244084826f1ce90c788c046545dcf21","width":300,"height":194}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Maintained strong financial position with $596 million in cash, cash equivalents and marketable securities as of March 31, 2026","length":127,"tagName":"p"}]},{"val":[{"type":"text","content":"Continued execution across the oncology pipeline, with a strategic focus on three priority programs: EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, EIK1003, a next-generation, highly selective PARP1 inhibitor, and EIK1005, a WRN helicase inhibitor","length":252,"tagName":"p"}]},{"val":[{"type":"text","content":"Six abstracts accepted for the American Society of Clinical Oncology (ASCO) annual meeting highlighting new data from the company’s lead programs including new safety, tolerability, and efficacy data ","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"Publication of a manuscript in the Journal of Medicinal Chemistry on the use of single molecule tracking (SMT) to advance chemical matter for discovery programs in the absence of robust biochemical assays","length":204,"tagName":"p"}]},{"val":[{"type":"text","content":"Roger M. Perlmutter, Board Chair and CEO, to participate in the Bank of America Securities 2026 Global Healthcare Conference in Las Vegas, May 12, 2026","length":151,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":933,"olType":false},{"type":"text","content":"MILLBRAE, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today reported first quar...